Clinical Trials
190 trialsPHL Treatment in Pancreatic Cancer
Fox Chase Cancer Center
Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer
Minia University
GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer
University of Illinois at Chicago
DUMELEP
Assistance Publique - Hôpitaux de Paris
Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
ARETHUSA
IFOM ETS - The AIRC Institute of Molecular Oncology
FOBEAR
Sun Yat-sen University
Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial
Sun Yat-sen University
COnCERTO
University Hospital, Rouen
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
Tang-Du Hospital
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
Universitätsmedizin Mannheim
Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma
Guangxi Medical University
RESET
Sixth Affiliated Hospital, Sun Yat-sen University
Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
PICC
Sun Yat-sen University
Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC
Sichuan Cancer Hospital and Research Institute
AB-LATE02
University Hospital, Montpellier
ESCC
Fujian Medical University Union Hospital
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Shanghai Zhongshan Hospital
Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer
Minia University
Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer
Changhai Hospital
NEONEC
GERCOR - Multidisciplinary Oncology Cooperative Group
Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
Shanghai Zhongshan Hospital
Neo-CRAG
Sun Yat-sen University
STELLARIII
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
EUS-RFA PANCARDINAL-1 Trial
The University of Texas Health Science Center, Houston
NEOGB
Rajiv Gandhi Cancer Institute & Research Center, India
Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
ADVANCE HCC
Ontario Clinical Oncology Group (OCOG)
PEACE
Azienda Unita Sanitaria Locale di Piacenza
NEEDS
Karolinska University Hospital
Prediction of Drug Response in Gastric Cancer Based on 3D Bioprinting
Peking Union Medical College Hospital
ESCC
Sichuan Cancer Hospital and Research Institute
NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC
RenJi Hospital
Neo-DRATEC
Zhejiang Cancer Hospital
Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy for Rectal Cancer: A Randomized Controlled Trial
Larissa University Hospital
CAP with NAT
Seoul National University Hospital
Anastomotic Leaks in Esophageal Squamous Cell Carcinoma Patients After Trimodal Therapy
Sun Yat-sen University
Predicting Gastric Cancer Response to Chemo With Multimodal AI Model
Sixth Affiliated Hospital, Sun Yat-sen University
ESOPEC
University Hospital Schleswig-Holstein
Prognostic Factors for Survival in Patients With Cholangiocarcinoma
Rigshospitalet, Denmark
Survival Analysis: TACE vs. Combination Therapy in HCC
Zhejiang University
Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer
Sun Yat-sen University
Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer
Seoul National University Hospital
Neoadjuvant Chemoradiotherapy Versus Total Neoadjuvant Therapy in the Treatment of T3 Rectal Cancer
St. James's Hospital, Ireland
A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC
First Affiliated Hospital of Fujian Medical University
Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
University of Nebraska
AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
Chinese Academy of Sciences
CAIRO4
Dutch Colorectal Cancer Group